Several gatekeeper mutations in the FGFR family have been reported in preclinical studies in several cancer models, including FGFR1 V561M in lung cancer [117,118], FGFR2 V565I/N550K/V564F in endometrial cancer and cholangiocarcinoma [116,119], FGFR3 V555M in myeloma [115] and FGFR4 V550L/V550E in rhabdomyosarcoma [120]. Here, FGFR4 is linked to lung cancer.